Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Looks like GTSIF is making a move up. They have solid research and are a potential winner.
Doji
MDMA is also going to be big in new PTSD treatments: https: https://www.medpagetoday.com/meetingcoverage/apa/92379?xid=nl_mpt_DHE_2021-05-03&eun=g1330593d0r&utm_source=Sailthru&utm_medium=email&utm_campaign=Daily%20Headlines%20Top%20Cat%20HeC%20%202021-05-03&utm_term=NL_Daily_DHE_dual-gmail-definition
MindMed is currently trialing MDMA: //www.prnewswire.com/news-releases/mindmed-announces-the-start-of-the-first-ever-clinical-trial-combining-mdma-and-lsd-301211436.html
DOJI
There is a probability for success here with DMT: https://www.sciencedirect.com/science/article/abs/pii/S0041134519306037
DOJI
The psychedelic space is currently where Cannabis was three years ago.
These are the Current Psychedelic companies that I am invested in:
MINE, MMEDF, MYCOF, RVVTF, LMLLF, EHVVF, NMLSF, HAVLF, TRMNF, CMPS,
FTRPF, SHRMF, CLXPF
Good luck to all.
DOJI
From 8 years ago:
Look at Claim #1 in the newly granted patent.
This covers a great deal more than just Psoriasis.
Doji
The invention claimed is:
1. A method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising: a. a carrier formulation comprising .beta.-caryophyllene, salicylic acid, and at least at least one of: i. glycerin; or ii. niacinamide; and b. cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from the group consisting of spongiotic dermatitides, psoriasiform dermatitides, interface dermatitides, bullous disease, dermatitides with perivascular inflammation, vasculitis, nodular and diffuse dermatitides, seborrheic dermatitis, lupus erythematosus, discoid lupus erythematosus, dermatomyositis, lichen planus, lichen sclerosus, lichen simplex chronicus, psoriasis, lichen striatus, lichen aureus, granuloma faciale, atopic dermatitis, sweet syndrome, granuloma inguinale, pyoderma gangrenosum, necrobiotic xanthogranuloma, pemphigus, pemphigus foliaceus, pemphigus vulgaris, dermatitis herpetiformis, erythema multiforme, follicular occlusion triad, ruptured cyst/follicle, cutaneous T-cells lymphoma, poison ivy, nummular dermatitis, and eczema.
DEA further de-scheduling CBD Oil: http://ir.gwpharm.com/press-releases
CBD companies that survive will have clear sailing in the future.
Doji
A full description of the OWC Oral Tablet trial mimicing the Sativex Dose: https://ichgcp.net/es/clinical-trials-registry/NCT03936907
Doji
This is the listing on the National Psoriasis foundation website. the new efficacy trial is not yet listed: https://trials.psoriasis.org/trials/NCT02976779
A full breakdown of the study can be found here: https://ichgcp.net/clinical-trials-registry/NCT02976779
Here is the registration for the first trial that has now completed. It was a Dose Study to Determine the Safety, Tolerability of of the cream: https://clinicaltrials.gov/ct2/show/NCT02976779
It is called "MGC cream" or "MCG ointment" and is a (now patented) Maximal dose of 30 mg CBD : 30 mg THC, 1:1 ratio or 3% THC and 3% CBD.
Doji
Here is the Medical Center in Israel where OWC will be conducting their Psoriasis trial. The Kaplan Medical Center.
https://www.owcpharma.com/wp-content/uploads/2019/08/August-2019_PR.pdf
https://hospitals.clalit.co.il/kaplan/en/Pages/default.aspx
Doji
It is a possibility that this dead horse may begin to rise. https://finance.yahoo.com/news/3-canadian-cbd-players-coming-163819451.html
Doji
Very good article out this morning on GW Pharma. This is a story that could mimic the future of OWCP if management gets it right.
Where Will GW Pharmaceuticals Be in 5 Years?
This frontrunner in cannabinoid research will continue to thrive.
https://www.fool.com/investing/2020/01/07/where-will-gw-pharmaceuticals-be-in-5-years.aspx
Doji
Very interesting interview with Dr. Hirsch concerning OWCP from Wall St Conference 2018:
Glad you like it.
Doji
Here is an excellent 2019 Research Paper discussing the use of cannabis in skin inflammation including the factors that cause Psoriasis:
https://www.researchgate.net/profile/Andrea_Magnavacca/publication/334086415_Cannabis_sativa_L_extract_and_cannabidiol_inhibit_in_vitro_mediators_of_skin_inflammation_and_wound_injury/links/5da46ecaa6fdcc8fc34fe7c2/Cannabis-sativa-L-extract-and-cannabidiol-inhibit-in-vitro-mediators-of-skin-inflammation-and-wound-injury.pdf
Sangiovanni, Enrico, et al. "Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury." Phytotherapy Research (2019).
Doji
Lot's of buying for the last 40 minutes off of today's low.
Not selling a single share of my early position.
I am in agreement with the longs that this may see 1$ in the next 30 days.
Doji
Take a look at the "Cannabis-based extracts and topical formulations for use in skin disorders" Patent application.
https://patents.google.com/patent/US20180042890A1/en
If you go to Google SCHOLAR and punch in these keywords:
"IL-8" "IL-33" "skin" "thc" "cbd" "1:1 ratio"
from the patent-pending claims, ONLY ONE hit shows up.
That is the OWCP Patent application.
For those non-IP folks out there, this means that this is some seriously NOVEL stuff, and has a very good chance of getting granted.
Doji
This is a pending claim in the Migraine IP for OWCP
https://patents.google.com/patent/WO2016092539A1/en
The composition of claim 1, wherein said composition is formulated for an administration route selected from the group consisting of: intranasal, transdermal, intravenous, vaginal, sublingual, buccal, oral, and any combination thereof.
Note that there is no VAPE or other Smokable version. This claim tells me that these guys understand that the worst way to take Cannabinoids for anything is through the lungs.
Look at all of the currently approved Cannabis Meds:
Epidiolex
Sativex
Marinol
Syndros
Dronabinol
They are ALL Orals. The reason is that smokable Marijuana is a pharmacological nightmare to do a study on.
Look at the first "POP" in volume in early October 2019.
There is about 90 day lag between getting "Notice of grant" from the PTO and an actual grant of a patent from the PTO. Possible more on the way.......
Doji
99% of all Cannabis based creams on the market have had ZERO testing and are not patented, and not well formulated or controlled.
https://badgerherald.com/news/2019/11/12/print-11-12-untested-cbd-products-could-be-potential-health-risk-as-cbd-sales-spike-aglhnd-ajs/
The OWCP product has both. A patent and it is actually undergoing clinical tests. This is a major differentiator.
Doji
Another possibility,OWC-1808:
A couple of years ago OWC released early data on OWC-1808, a "high potency" formulation of 50%CBD and 50%THC for treatment of Multiple Myeloma. This premise has had success in other clinical trials.
Multiple Myeloma:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5363603/
Anti-Cancer in general:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6609248/
The whole concept of Cannabinoids working to potentiate traditional chemotherapy is a big deal. OWC is currently applying for a license to test this product (possibly already granted)in animals through the Israel Medical Cannabis Agency (IMCA)
https://investinisrael.gov.il/Documents/RoundTable/medical-cannabis-doc250919.pdf
OWC is most likely doing this through Pharmaseed LT in Israel: http://www.pharmaseedltd.com/in-vivo-models/cannabis-based-medicine/
This is from the May 2019 S-1: https://seekingalpha.com/filing/4515332
"PharmaSeed/Science in Action:1. Three Preclinical Studies, A MTD study with our 1808 delivery formulation was found safe and tolerable"
Next on their list is applying for a "Pre-Clinical R&D on Orphan or Life Threatening Diseases" designation in 2020 with the 1808 delivery formulation. See pg 16 from here:
https://www.owcpharma.com/wp-content/uploads/2019/05/OWC-Company-PPT_March-2019_V1-ICR-1-5-19-3.pdf
This could be another VERY interesting piece of the puzzle that is moving OWCP forward.
Doji
Here is a nice PPT from OWC: https://www.owcpharma.com/wp-content/uploads/2019/05/OWC-Company-PPT_March-2019_V1-ICR-1-5-19-3.pdf
Seems that they are hitting some of their stated milestones.
Look at slides 12-17.
Doji
This is where the biggest play will be in this company.
https://www.otcmarkets.com/stock/OWCP/news/OWC-Pharmaceutical-Research-Corp-to-Report-Top-Line-Results-TLR-for-a-Safety-Study-on-Its-Cannabis-based-Tablets?id=242527
RAMAT GAN, Israel, Oct. 7, 2019
The TLR show that both MGC-ODT and Sativex® administration had comparable mean times of peak concentration, half-life and elimination rates for each of the three analytes (THC, THC metabolite 11-hydroxy-THC and CBD). The results indicated dose-related comparability of both products in rate of absorption and bioavailability. The incidence of treatment related adverse events (AEs) were similar between the treatments.
Top Line Results Conclusions: OWC- Orally Disintegrating Tablet is safe to use and appears to have similar PK and bioavailability as Sativex®. Therefore, OWC intends to apply to the Israel Ministry of Health to obtain necessary approvals to market its Medical Grade Cannabis - Orally Disintegrating Tablets in Israel.
If this is ultimately approved by the US FDA, look out.............
Doji
This is in my view the most interesting study the company has undertaken:
Comparison of Safety, Tolerability and Pharmacokinetics of Medical Grade Cannabis (MGC) Orally Disintegrating Tablets With Buccal Sativex®, in Healthy Adult Volunteers
https://clinicaltrials.gov/ct2/show/record/NCT03936907?term=%22One+World+Cannabis%22&rank=1
As there are no end to the Charlatans staffing Medical Marijuana dispensaries around the country, without a clue as to proper dosing parameters for their products, a true dissolvable "oral" that would give the same reliable dose as Sativex (tested and proven for the last 20 years) would be a very big win.
Doji
All currently approved (US and abroad)Medical marijuana products are orals.
Epidiolex
Sativex
Marinol
Syndros
Dronabinol
There are specific reasons for this, including the fact that smoking and vaping Cannabinoids give fundamentally incorrect PK/PD dosing profiles.
If OWC truly has new (and patented) working oral delivery systems, then they have a business, and partnerships should follow.
Doji
New spending bill about to be passed in congress.
http://www.washingtonpost.com/blogs/post-politics/wp/2014/12/09/whats-in-the-spending-bill-we-skim-it-so-you-dont-have-to/
MARIJUANA:
The District of Columbia will be prohibited from legalizing marijuana for the much of the coming year. The development -- upending a voter-approved initiative -- shocked elected D.C. leaders, advocates for marijuana legalization and civil liberties groups. The bill also would block the Justice Department from interfering with state-level medical marijuana measures and prohibits the Drug Enforcement Agency from interfering with industrial hemp production.
Global Biofuel Production predicted to be higher in 2015 than in 2013 or 2014, at 2.20 million barrels/day.
http://www.upstreamonline.com/marketdata/marketdata_content/IEA_Oil_Report/article1384723.ece/binary/IEA%20Oil%20report
http://business.financialpost.com/2014/11/26/opec-has-another-problem-weak-demand/?__lsa=570b-9c60
Government support for biofuels, electric and natural-gas powered vehicles, and increased fuel economy were all introduced to support climate change goals as much as energy security. Climate change will give energy efficiency policies much more stickiness than in the 1980s and 1990s.
In that sense, OPEC may face a bigger challenge in using low prices to buy back some of the demand growth lost in recent years. The rapid modernization of developing economies will work in the cartel’s favor, but climate change policy works against it, as OPEC tries to rebalance the market.
Every day, more and more major players are starting to use biofuels.
http://www.business-standard.com/article/government-press-release/indian-railways-to-go-for-bio-diesel-in-a-big-way-114110500702_1.html